Patients with acute coronary syndromes and elevated levels of natriuretic
peptides: the results of the AVANT GARDE-TIMI 43 Trial.
Author(s): Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Oude Ophuis AJ, Lopez-Sendon J,
Swedberg K, Ogorek M, Rifai N, Lukashevich V, Maboudian M, Cannon CP, McCabe CH,
Braunwald E.
Affiliation(s): TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75
Francis Street, Boston, MA 02115, USA. bscirica@partners.org
Publication date & source: 2010, Eur Heart J. , 31(16):1993-2005
AIMS: Elevated natriuretic peptides (NPs) are associated with an increased
cardiovascular risk following acute coronary syndromes (ACSs). However, the
therapeutic implications are still undefined. We hypothesized that early
inhibition of renin-angiotensin-aldosterone system (RAAS) in patients with
preserved left ventricular function but elevated NPs but following ACS would
reduce haemodynamic stress as reflected by a greater reduction NP compared with
placebo.
METHODS AND RESULTS: AVANT GARDE-TIMI 43 trial, a multinational, double-blind
trial, randomized 1101 patients stabilized after ACS without clinical evidence of
heart failure or left ventricular function
|